Immune checkpoint inhibitors (ICIs) that target the programmed cell death protein-1 (PD-1)/programmed death receptor ligand-1 (PD-L1) axis or cytotoxic T lymphocyte antigen 4 (CTLA4) have achieved impressive success against various cancer types (3). Here, CD274 is linked to cancer.